<div id="ectolysins-against-gram-postitive-bacteria" class="gg-light">
  <div class="centerize ctz-lg px-3 py-5 gg-japanese-laurel anim-hidden fade-in-up">
    <h2 class="text-center fw-900">Ectolysins against Staphylococcus</h2>
	<p style="font-size:1.4rem; line-height:2;">Ectolysin P128, GangaGen’s lead molecule is a chimeric recombinant anti-staphylococcal protein that targets both coagulase positive and coagulase negative Staphylococci.</p> 
    <p style="font-size:1.4rem; line-height:2;">P128 has a novel mechanism of action and rapidly kills Staphylococci.</p>
	<p style="font-size:1.4rem; line-height:2;">It is proven to be very effective both in vitro &amp; in vivo against multidrug resistant pathogens like Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Staphylococcus aureus (VRSA) and Daptomycin Resistant Staphylococcus aureus (DRSA). GangaGen has completed Phase I/IIA studies with P128 for ‘nasal decontamination of S. aureus’ from human nares.</p>	
  </div>
</div>

<div class="gg-japanese-laurel gg-light-text" style="border-bottom:solid 3px var(--gg-light);">
  <div class="centerize ctz-lg px-3 py-5">
    <h2 class="fw-900 text-center anim-hidden fade-in-down">Ectolysins against Enterococcus</h2>
	<p class="anim-hidden fade-in-up" style="font-size:1.4rem; line-height:2;">GangaGen has used PATP to discover and engineer novel ectolysins suitable for multiple applications.</p>
  </div>
</div>